EQT Reportedly Submits Binding Offer Above $50/Share for Qiagen

The Reuters-carried Bloomberg report explicitly states that EQT is in advanced talks to acquire Qiagen and has submitted a binding offer above $50 per share. This is a new, forward-looking merger-and-acquisition development with direct implications for Qiagen and EQT, although the report does not disclose the exact price or confirm Qiagen’s acceptance or transaction closing. Importance is set at 0.80 because a binding offer for a public company is a material catalyst, while surprise is moderated to 0.62 because earlier context had already reported preliminary takeover interest and possible bids of at least $50 per share. Confidence is 0.82 for the core reported facts but not higher because the information is secondhand and the offer remains unconfirmed by the parties. The occurrence date is estimated as October 20, 2026; the exact submission time is unavailable, so the timestamp uses the start of that UTC date with limited timestamp confidence. QGEN and EQT.ST are approved as the direct target and bidder. MC and GS are also approved because the supplied context identifies them as Qiagen strategic-review advisers whose prospective advisory work could be affected; other peers and prior potential bidders are excluded because their effects are speculative or insufficiently direct. The prior matching decision is retained: this is not a duplicate, and it warrants a new merger-and-acquisition event rather than being standalone.